Clinical Trial Update: Randomized Controlled Trial of CAN-2409 Immunotherapy During Active Surveillance for Prostate Cancer (ULYSSES) [Phase 2]

View source ↗

Summary

Phase 2 randomized trial evaluating CAN-2409 immunotherapy during active surveillance for prostate cancer (ULYSSES) is currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• CAN-2409

Snippet

Sponsor: Candel Therapeutics, Inc. | Conditions: Prostate Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING